Skip to content

Clinical News

A gathering to showcase the health of oncology research in Ireland

Paul Mulholland reports on the recent ISMO Fellowship and Bursary Awards meeting The 2020 Irish Society of Medical Oncology (ISMO) Fellowship and Bursary Awards took place in the Catherine McAuley Centre, Mater Misericordiae University Hospital, Dublin, on Friday and Saturday 24 and 25 January. As usual, the meeting featured some of the very best oncology…

Read More

Diagnosing and treating psoriasis

Dr Donna Cosgrove PhD, Pharmacist, takes a clinical look at the diagnosis, impact and treatment of different presentations of psoriasis and how the pharmacist can improve quality of life for these patients Psoriasis is a multifactorial, chronic, multi-system, inflammatory disease with mainly skin and joint involvement. It can cause itching, irritation, burning, and stinging and…

Read More

Management of atopic eczema

Atopic eczema, also known as atopic dermatitis, is a chronic, inflammatory skin disorder characterised by intense itching, dry skin, and recurrent erythematous lesions, which usually develops in early childhood The causes of atopic eczema remain unclear, but are multifactorial in nature, involving genetic, socioeconomic, and environmental factors. It can run in families and often develops alongside other atopic…

Read More

A topical take on dermatology

The annual three-day scientific meeting of the Primary Care Dermatology Society of Ireland (PCDSI) gets underway in Cork at the end of February. Niamh Cahill speaks to PCDSI chairperson Dr Karen Reidy to preview the meeting he 23rd annual meeting of the Primary Care Dermatology Society (PCDSI) will take place at the Rochestown Park Hotel,…

Read More

Depression: Updates on diagnosis and treatment

According to the World Health Organisation (WHO), depression is now the leading cause of ill health and disability worldwide Around the globe, more than 300 million people are living with depression, which represents an increase of more than 18 per cent between 2005 and 2015. Over the course of a life-time, the risk of developing…

Read More

Prescribing antipsychotic medication in the treatment of schizophrenia

Case report A 33-year-old female with a known diagnosis of schizophrenia was attending an outpatient psychiatric clinic. She had first developed symptoms of psychosis two years earlier when she became paranoid and thought people were laughing at her. She also believed that she could hear two people plotting her demise and she felt convinced that…

Read More

Updated EULAR recommendations on gout

Priscilla Lynch outlines the new 2018 updated European League Against Rheumatism (EULAR) evidence-based recommendations for the diagnosis of gout In 2006, EULAR produced its first evidence-based recommendations for the diagnosis of gout. Since then, major advances have been made with regard to imaging, clinical diagnosis and understanding of the natural history of the disease. A…

Read More

Down syndrome and inflammatory arthritis

There are distinct immune cell responses in children with Down syndrome and inflammatory arthritis, which are associated with an aggressive erosive disease Down syndrome (DS) is a common chromosomal disorder characterised by the presence of a full or part of a third copy of chromosome 21. A variety of medical conditions are associated with DS, including…

Read More

Can we predict disease onset for rheumatoid arthritis?

There is a major need to be able to predict the efficacy of drugs for the treatment of rheumatoid arthritis Rheumatic and musculoskeletal diseases (RMD) affect up to 60 per cent of the 120 million EU citizens, at an estimated cost of €240 billion, with direct costs of 2 per cent EU GDP. Rheumatoid arthritis…

Read More

PARP inhibitors in cancer – shifting the paradigm to frontline treatment

The last decade has seen major advances in oncology therapy with the addition of PARP inhibitors, with significant updated data on their usage across a range of cancers in the last 12 months Tubo-ovarian cancer The last 12 months has continued to see PARP inhibitors lead the field as regards therapeutic advancement in advanced tubo-ovarian…

Read More
Scroll To Top